Q-omics provides the consensus-scored SMC1A profile across patient tissues and cancer cell-line models. SMC1A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SMC1A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SMC1A protein abundance shows 38,620 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where SMC1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMC1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMC1A survival associations across molecular data types. SMC1A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMC1A RNA expression–survival associations across cancer types. High SMC1A expression shows unfavorable associations in MESO, ACC, KICH and LIHC, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SMC1A RNA expression.
This table summarizes SMC1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SMC1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMC1A shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, STAD and LUSC. The HNSC box plot shows higher SMC1A RNA expression in tumor versus normal tissue (log2 FC = +0.938, t-test p < 0.001).
This table shows molecular features associated with SMC1A in patient tissues and cancer cell lines. In patient samples, SMC1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMC1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
